When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients?
- 1 September 2007
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 93 (5) , 491-492
Abstract
We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable.Keywords
This publication has 7 references indexed in Scilit:
- Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast CancerCancer Investigation, 2006
- Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapiesClinical and Translational Oncology, 2006
- Brain Metastases in Patients with Breast Cancer: New HorizonsClinical Breast Cancer, 2005
- Central nervous system metastases in breast cancer patients administered trastuzumabCancer Treatment Reviews, 2005
- Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBritish Journal of Cancer, 2004
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001